Q3 2022 Targovax ASA Earnings Call Transcript
Welcome to Targovax and the presentation of our third quarter results. My name is Erik Digman Wiklund. I'm the CEO at Targovax. With me today, I have Chief Financial Officer, Lubor Gaal; as well as Chief Scientific Officer, Victor Levitsky.
To remind you, Targovax is a biotech company developing novel immunotherapies for treatment of cancer. We have 3 major pillars in our development program. Number one, our lead clinical stage asset is ONCOS-102. This is an oncolytic adenovirus which we deliver directly into tumors. Our core focus here is in PD-1-resistant melanoma. This is aggressive skin cancer that has become resistant to other immunotherapies, and we try to reactivate the response by using our highly inflammatory oncolytic virus, ONCOS-102. The next step here is to start a Phase II trial next year in the PD-1-resistant setting, and I'll come back to some updates from this study.
Our second clinical stage program is a mutant KRAS neoantigen vaccine. This is called TG. With the KRAS program, we are preparing to initiate 2 investigator-sponsored
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investorsā 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
